Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24

Rhea-AI Summary

Stonegate Capital Partners has updated its coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for the second quarter of 2024. This update provides investors with fresh insights into the company's performance and market position. Bio-Path Holdings is a biotechnology company focused on developing innovative therapies using its proprietary DNAbilize® antisense RNAi nanoparticle technology. The update from Stonegate Capital Partners, a respected financial research firm, is likely to offer valuable analysis on Bio-Path's recent developments, financial health, and future prospects in the competitive biotech sector.

Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2024.

To view the full announcement, including downloadable images, bios, and more, click here.

Click image above to view full announcement.

---

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222180

FAQ

What is the significance of Stonegate Capital Partners updating coverage on Bio-Path Holdings (BPTH)?

Stonegate Capital Partners updating coverage on Bio-Path Holdings (BPTH) is significant as it provides investors with fresh, professional analysis of the company's performance, financial health, and market position for Q2 2024. This can help investors make more informed decisions about BPTH stock.

When was the coverage update for Bio-Path Holdings (BPTH) released by Stonegate Capital Partners?

The coverage update for Bio-Path Holdings (BPTH) was released by Stonegate Capital Partners on September 4, 2024, focusing on the company's performance in the second quarter of 2024.

What is Bio-Path Holdings' (BPTH) main focus as a biotechnology company?

Bio-Path Holdings (BPTH) is primarily focused on developing innovative therapies using its proprietary DNAbilize® antisense RNAi nanoparticle technology. This technology is aimed at creating new treatments in the biotechnology sector.

Where is Bio-Path Holdings (BPTH) stock traded?

Bio-Path Holdings (BPTH) stock is traded on the NASDAQ stock exchange.